Moderna (MRNA) Announces First Patient Dosed with Booster, Data Could Indicate Increased Supply - Morgan Stanley

March 11, 2021 7:17 AM EST Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $201.00 price target on Moderna (NASDAQ: MRNA) after management announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login